Pharmaceuticals News and Research

RSS

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Centocor Ortho Biotech Products withdraws NDA for trabectedin for treatment of women with ROC

Centocor Ortho Biotech Products, L.P., today announced that it has voluntarily withdrawn the New Drug Application for trabectedin for the treatment of women with recurrent ovarian cancer. The withdrawal is based on the U.S. Food and Drug Administration's recommendation that an additional Phase 3 study be conducted to obtain approval.

30 Apr 2011

Winner of MDEA Lifetime Achievement Award announced

UBM Canon's Medical Design Excellence Awards has announced the winner of the Medical Design Excellence Awards Lifetime Achievement Award. This award honors an individual whose contributions during a long career have had a demonstrable impact on technological, business, and cultural advancements in medical devices.

30 Apr 2011

Healthcare advertising agencies earn Med Ad News recognition

UBM Canon has announced the winners of the 22nd annual Med Ad News Manny Awards 2011. The gala event, held at the Sheraton New York Hotel and Towers, culminated with the naming of AbelsonTaylor Inc. as Agency of the Year: Category I.

30 Apr 2011

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced its results for the first quarter ended March 31, 2011.

30 Apr 2011

NeurogesX first quarter revenue is $3.2 million for 2011

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its first quarter ended March 31, 2011.

30 Apr 2011

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

Aptilon annual revenue increases 111% to $33.5 million

Aptilon Corporation, a leader in online access, engagement and interaction with physicians and healthcare professionals on behalf of pharmaceutical and life sciences companies, today announced its financial results for the year ended December 31, 2010.

30 Apr 2011

Magellan reports net revenue of $692.8 million for first quarter 2011

Magellan Health Services, Inc. today reported financial results for the first quarter of 2011, as summarized below, and increased guidance for the full year.

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.

29 Apr 2011

China Pharmaceuticals net sales increase 28% to $34,184,906

China Pharmaceuticals, Inc., one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals today announced its financial results for fiscal year ended December 31, 2010.

29 Apr 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

Bayer expands sponsorship agreement with World Federation of Hemophilia

Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia are announcing a three-year extension of Bayer's sponsorship agreement with WFH.

29 Apr 2011

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company's proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant funding by the Massachusetts Life Sciences Center.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Lithium shows hope for Alzheimer’s disease

According to scientists Alzheimer’s disease, a progressively damaging motor neuron condition, could be treated by lithium, a naturally occurring element that is extremely inexpensive and already in use for other psychiatric disorders.

29 Apr 2011

Drug subsidy issues out of PBS’ hands - almost

According to Health Minister Nicola Roxon, expensive drugs have never been automatically listed for subsidy and they can't be now when the government controlling expenses. She added that federal Labor has to balance competing priorities in health and every other department.

29 Apr 2011